

Suven Lifesciences receives five patents from four countries

17 December 2014 | News | By BioSpectrum Bureau

Suven Lifesciences receives 5 patents from 4 countries



Singapore: India-based Suven Lifesciences has secured patents for its new chemical entities (NCEs) from Japan, China, New Zealand, and Israel. The company has received two product patents from Israel and one each from the other countries.

The NCEs have a potential to treat disorders associated with neurodegenerative diseases. The drugs were developed as therapeutic agents to be used in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's, attention deficiency hyperactivity disorder (ADHD), Huntington's, Parkinson and schizophrenia diseases.

The company, in a filing to the BSE said that, the patents includes the class of selective 5-HT compounds discovered by Suven. Earlier this year too, the company had received patents for its innovative products. With these new patents, Suven has two granted patents from Israel, 11 from Japan, 15 from China and 21 from New Zealand.

"We are very pleased by the grant of these patents to Suven for pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally," said Mr Venkat Jasti, CEO of Suven.